StockNews.com Lowers DexCom (NASDAQ:DXCM) to Hold

StockNews.com downgraded shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a report published on Saturday morning.

A number of other equities analysts have also recently weighed in on DXCM. Robert W. Baird increased their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a neutral rating in a research report on Monday, August 5th. Stifel Nicolaus raised their price target on shares of DexCom from $90.00 to $100.00 and gave the company a buy rating in a research report on Friday, August 23rd. Wells Fargo & Company decreased their price target on shares of DexCom from $145.00 to $80.00 and set an overweight rating for the company in a research report on Friday, July 26th. Morgan Stanley decreased their price target on shares of DexCom from $120.00 to $75.00 and set an equal weight rating for the company in a research report on Friday, July 26th. Finally, Baird R W cut shares of DexCom from a strong-buy rating to a hold rating in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $110.69.

DexCom Stock Down 0.5 %

Shares of NASDAQ DXCM opened at $69.21 on Friday. The company has a 50 day simple moving average of $70.17 and a 200-day simple moving average of $102.62. The company has a market capitalization of $27.52 billion, a P/E ratio of 44.65, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 EPS. On average, equities research analysts predict that DexCom will post 1.69 earnings per share for the current year.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,824 shares of company stock valued at $126,390. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the second quarter valued at $25,000. Sachetta LLC increased its stake in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the period. Crewe Advisors LLC acquired a new position in DexCom in the first quarter valued at $29,000. Riverview Trust Co acquired a new position in DexCom in the first quarter valued at $32,000. Finally, DT Investment Partners LLC increased its stake in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.